Urogenic Neoplasms

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-06-25
EMA Authorised: Padcev (Enfortumab vedotin) — Astellas Pharma Europe B.V.
EMA authorised Padcev (enfortumab vedotin) for conditions within transitional cell carcinoma and urologic neoplasms.